Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.57 |
| ▸ | FNTB | P49356 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460432 | 0.92 | FNTA (0.52) | FNTAFNTBMAPTKLK7KLK5 | |
| SCHEMBL29460422 | 0.89 | FNTA (0.50) | FNTAFNTBMAPTMEN1KMT2A | |
| SCHEMBL29460392 | 0.89 | KLK7 (0.56) | MAPTKLK7KLK5CA1 | |
| SCHEMBL22207315 | 0.85 | FNTA (0.50) | FNTAFNTBMAPTMEN1KMT2A | |
| SCHEMBL22207314 | 0.85 | FNTA (0.50) | FNTAFNTBMAPTMEN1KMT2A | |
| SCHEMBL29460390 | 0.83 | KLK7 (0.51) | MAPTKLK7KLK5PAX8TDP1 | |
| SCHEMBL31374712 | 0.82 | CA1 (0.49) | MAPTMEN1KMT2ANPSR1KLK7 | |
| SCHEMBL29460388 | 0.82 | KLK7 (0.61) | MAPTMEN1KMT2ANPSR1KLK7 | |
| SCHEMBL29460398 | 0.80 | TDP1 (0.45) | FNTAFNTBMEN1KMT2AKLK7 | |
| SCHEMBL439919 | 0.78 | KLK7 (0.61) | MAPTMEN1KMT2ANPSR1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | ASTELLAS PHARMA INC. (JP) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | FNTA 3783/4885FNTB 2067/4885MAPT 3740/4885 |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | SIGLEC7, TNFSF11, FCGR2A | FNTA 3370/4885FNTB 1866/4885MAPT 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.